Overview
NICE is unable to make a recommendation on subcutaneous spesolimab (Spevigo) 1-ml formulation for preventing generalised pustular psoriasis flares in people 12 years and over. This is because the company did not provide an evidence submission.
Last reviewed: 08 April 2026
Next review: We will review this decision if the company decides to make a submission.